

PDX Data Sheet for COG-N-672x

Disease: Neuroblastoma
Phase of Therapy: Post-Chemotherapy (Progressive Disease), Post-mortem
Treatment: ANBL00B1 (Chemotherapy, Surgery)
Disease Stage: 4
Gender: Male
Age at diagnosis: 20.2 months
Race: NA
Age at sample collection: 26.3 months
Source of culture: Blood October 2017
Primary tumor site: Adrenal gland
Date Established: December 2017

MYCN Patient: Amplified
MYCN PDX: Relative copy number – NA
TH mRNA: NA
p53 functionality: NA
Telomere Mechanism: NA
ALK: NA

PDX RNAseq: Available upon request
PDX WES: Available upon request
Strain of Mice: NSG or Athymic NuNu (recommended)
Injection Type: Subcutaneous
Growth Properties: 10e6 cells minimum, ~2 months to 1500mm³
 Please see Protocols section at
<https://www.cccells.org/protocols.php>

Human vs. Mouse: This PDX model has been tested and confirmed over multiple passages to be above 90% human cells.

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: The Childhood Cancer Repository has a matching direct-to-culture cell line available from this same patient – COG-N-672. The Childhood Cancer Repository has a matching hypoxic cell line grown at 5% O₂ and 2% O₂ available from this same patient – COG-N-672h and COG-N-672h2.

h-IMPACT Profile I IDEXX: PCR evaluation of EBV, HAAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul, Sin Nombre, VZV were all negative.

PDX Data Sheet for COG-N-672x

Cell Line Name: COG-N-672x

References:



PDX Data Sheet for COG-N-672x

PDX Name: COG-N-672x

H&E slides